<DOC>
	<DOC>NCT00749138</DOC>
	<brief_summary>A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.</brief_summary>
	<brief_title>Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy</brief_title>
	<detailed_description>Six different dosages of tamoxifen will be given for 14 days with safety and viral loads being measured.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1. HCV RNA positive. 2. failed standard therapy 1. Cirrhosis on biopsy 2. Severe medical or psychiatric conditions that would make the evaluation difficult 3. Tamoxifen is a pregnancy category D drug so pregnant women must be excluded. 4. Patients with coumadin cannot be used from a drug interaction. 5. Active use of alcohol or illegal substances</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>hepatitis C, tamoxifen</keyword>
</DOC>